Who are we?


Signup for

Online registration

Log in to register
your trial

Search a trial




van CCT (UK)

van CCT (UK)

The TURN trial, Transplantation of faeces in Ulcerative colitis; Restoring Nature's homeostasis.

- candidate number9357
- NTR NumberNTR2862
- ISRCTNISRCTN wordt niet meer aangevraagd.
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR21-apr-2011
- Secondary IDs11/005 MEC AMC
- Public TitleThe TURN trial, Transplantation of faeces in Ulcerative colitis; Restoring Nature's homeostasis.
- Scientific TitleTransplantation of faeces in Ulcerative colitis; Restoring Nature's homeostasis.
- hypothesisWe hypothesize that faecal transplantation from a healthy donor can restore the dysbiosis present in UC patients, thereby inducing remission of the chronic inflammation of the colonic mucosa.
- Healt Condition(s) or Problem(s) studiedInflammatory bowel disease, Ulcerative Colitis
- Inclusion criteria1. Patients 18 years or older;
2. Established ulcerative colitis with known involvement of the left colon;
2. Simpe Clinial Colitis Activity Index of > 4 and < 11;
3. Endoscopic Mayo score of > 1;
4. In case of use of medication: Stable dose of thiopurines, 5-ASA, or corticosteroids in preceding 8 weeks.
- Exclusion criteria1. Condition leading to profound immunosuppression;
2. Anti-TNF treatment in preceding 2 mths;
3. Ciclosporine treatment in preceding 4 wks;
4. Use of Methotrexaat in preceding 2 mths;
5. Prednisolone dose > 10 mg;
6. Life expectancy < 12 mths;
7. Use of systemic antibiotics in preceding six weeks;
8. Use of probiotic treatment in preceding 6 weeks;
9. Positive stool cultures for common enteric pathogens (Salmonella, Shigella, Yersinia, Campylobacter, enteropathogenic e coli);
10. History of surgery: hemicolectomie (defined as: surgery resulting in a resection of > 1/2 of the colon), presence of a pouch due to surgery, presence of stoma;
11. Known intra-abdominal fistula;
12. Pregnancy or women who give brestfeeding;
13. Vasopressive medication, icu stay;
14. Signs of ileus, diminished passage;
15. Allergy to macrogol or substituents, eg peanuts, shellfish.
- mec approval receivedyes
- multicenter trialno
- randomisedyes
- masking/blindingDouble
- controlPlacebo
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 21-apr-2011
- planned closingdate31-dec-2012
- Target number of participants40
- InterventionsArm 1: Patients will be treated with faecal transplantation, processed for duodenal-tube infusion;
Arm 2: Patients will be treated with their own faeces (placebo), processed for duodenal-tube infusion.
- Primary outcomeCo-primary endpoint of clinical remission, as well as reduction of Mayo endoscopic inflammation score at 12 weeks after treatment.
- Secondary outcome1. SCCAI score reduction at t=6 weeks;
2. intra individual changes in faecal samples and mucosal biopsies;
3. Frequency of bowel movements;
4. Time to recurrence.
- TimepointsWeek: 0, 3, 6, 12, 16, 24, 32, 40 and 52.
- Trial web siteN/A
- statusstopped: trial finished
- Sponsor/Initiator Academic Medical Center (AMC), Amsterdam
- Funding
(Source(s) of Monetary or Material Support)
Academic Medical Center (AMC), Amsterdam, ZON-MW, The Netherlands Organization for Health Research and Development
- PublicationsN/A
- Brief summaryUlcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) of the colon. Complaints such as abdominal pain, cramps and bloody diarrhoea usually start in early adulthood and lead to life-long substantial morbidity. There is no medical treatment available that meets the desired criteria of high efficacy versus low adverse effects. The current prevailing hypothesis regarding the cause of UC states that the pathogenesis involves an inappropriate and ongoing activation of the mucosal immune system driven by the intestinal microbiota in a genetically predisposed individual. Systematic investigation into the effect of correcting the dysbiosis in ulcerative colitis patients has never been performed. The most radical way to restore the presumably disturbed natural homeostasis in UC is to perform faecal transplantation from a healthy donor. In this trial the potential beneficial effects of restoring microbial homeostasis by faecal transplantation through a duodenal tube will be studied in a phase II randomised placebo controlled design.
Endpoints are clinical remission and reduction of endoscopic inflammation after 12 weeks (primary), as well as time to recurrence, intra individual changes in faecal samples and mucosal biopsies. Follow up is 12 months.
- Main changes (audit trail)
- RECORD21-apr-2011 - 21-dec-2014

  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar